Opinion
‘Impressive’ SOLO3 results should influence practice
Dr. Alan P. Lyss reviews data showing that olaparib outperformed chemotherapy in patients with heavily pretreated ovarian cancer.
Opinion
Perspective from the heartland: Cancer care and research during a public health crisis
Dr. Alan P. Lyss examines how the COVID-19 pandemic has and will affect cancer care and research.
Opinion
Responsible use of breast cancer screening
Dr. Alan P. Lyss reviews a study suggesting that women aged 75 years and older do not benefit from annual mammography.
Opinion
Real-world data are a wake-up call
Dr. Alan P. Lyss analyzes research showing treatment doesn’t correspond to guidelines in breast cancer patients with deleterious germline...
Opinion
The possibilities of pembrolizumab plus chemo in breast cancer treatment
Dr. Alan P. Lyss reviews studies of breast cancer patients receiving pembrolizumab in combination with chemotherapy.
Opinion
Guidelines for today and tomorrow
Dr. Alan P. Lyss comments on guidelines for genetic testing in epithelial ovarian cancer and data that support a reexamination of colorectal...
Opinion
New tools could help predict complication risks in lung and breast cancer
More evidence is needed before clinicians can rely on these new tools.
Opinion
ctDNA and avapritinib in GI cancer management
Dr. Alan P. Lyss breaks down how circulating tumor DNA monitoring and the approval of a new targeted agent are both set to change management of...
Opinion
New evidence informs discussions on FL treatment and breast screening
Dr. Alan P. Lyss explores recent studies on rituximab maintenance in follicular lymphoma and the use of MRI as a supplemental screening for women...
Opinion
The clinical impact of new approvals in sickle cell, MCL
Dr. Alan P. Lyss puts some recent FDA approval of crizanlizumab and zanubrutinib into perspective for clinicians.
Opinion
Expanding the reach of available cancer therapies
Dr. Alan P. Lyss highlights two articles that demonstrate the safety of established treatments – nephrectomy and stereotactic ablative body...
Opinion
‘You had me at hello’: ESMO studies confirm survival benefits in NSCLC and breast cancer
Dr. Alan P. Lyss reflects on the significance of two studies from ESMO 2019 that show significant survival improvements in NSCLC and breast cancer...
News
Is it time to expand the use of PARP inhibitors?
Dr. Alan P. Lyss breaks down new findings presented at the European Society of Medical Oncology Congress on the expanded use of PARP inhibitors in...
Opinion
The law of unintended consequences
Dr. Alan P. Lyss examines the impact of women’s health clinic closures and excessive radiation doses in some lung cancer screening programs.
Opinion
NSCLC: Predicting benefit from immunotherapy plus chemo
Dr. Alan P. Lyss reviews three studies presented at the World Conference on Lung Cancer on the use of tissue biomarkers in predicting the benefit...